Search / Trial NCT00000156

The Effects of Light Reduction on Retinopathy of Prematurity (Light-ROP)

Launched by NATIONAL EYE INSTITUTE (NEI) · Sep 23, 1999

Apply for Trial

Trial Information

Current as of September 08, 2024

Completed

Keywords

Description

Despite progress during the past decade in treatment of ROP, this disease still poses a significant (approximately 2.1 percent) risk of blindness to extremely low birth-weight (\<1,251 grams) preterm infants. Current estimates indicate that about 27,000 infants of extremely low birth weight are born annually, of which 74 percent will survive. As techniques of managing smaller and less mature preterm infants continue to improve, it is expected that the number of infants at risk for blindness will continue to increase. For infants weighing less than 1,251 grams at birth, the Cryotherapy for ...

Gender

ALL

Eligibility criteria

  • Premature infants weighing less than 1,251 grams at birth and having a gestational age of less than 31 weeks were eligible for randomization. Consent must have been obtained within 24 hours of birth. Patients with major congenital anomalies are excluded.

About Sponsor

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Buffalo, New York, United States

Dallas, Texas, United States

San Antonio, Texas, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0